Skip to content

Effect of Wuweixiaodu Decoction on Clinical Efficacy and Inflammatory Factors of Acute Gouty Arthritis

Effect of Wuweixiaodu Decoction on Clinical Efficacy and Inflammatory Factors of Acute Gouty Arthritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047807
Enrollment
Unknown
Registered
2021-06-26
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gouty Arthritis

Interventions

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the informed consent form before the trial-related activities, be able to understand the procedures and methods of the trial, and be willing to strictly abide by the clinical trial protocol to complete the trial; 2. Age between 18-75 years old, male or female; 3. Patients who meet the 1977 or 2015 ACR (American College of Rheumatology) classification and diagnosis criteria for gout, and have been identified by professional doctors as moderate to severe activity in the acute arthritis stage, and the TCM differentiates the disease as damp-heat accumulation type.

Exclusion criteria

Exclusion criteria: 1. Persons who are considered by researchers to have poor compliance and affect the evaluation of drug safety and effectiveness; persons who abuse drugs; 2. Patients with renal failure and liver damage (transaminase greater than three times the upper limit of normal); 3. Those who are allergic to various drugs in the program; 4. Patients with a history of chronic heart disease, malignant tumors, recurrent infectious diseases, peptic ulcers, and low blood levels; 5. Suffering from other diseases that may confuse gouty arthritis, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, Sj?gren's syndrome and other diseases; 6. Pregnant women and lactating women.

Design outcomes

Primary

MeasureTime frame
interleukin-1ß;Cytokines IL-2, 4, 6, 10, TNF-a, IL-10, IFN-?;Uric acid;erythrocyte sedimentation rate;C-reactive protein;

Countries

China

Contacts

Public ContactLin Na

The First Affiliated Hospital of Zhejiang Chinese Medical University

linna_0314@163.com+86 15957164089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026